Cao et al. (2007) found that the PPARγ agonist rosiglitazone could directly increase the expression of PTEN and block the PI3K/AKT transduction pathway to inhibit the growth of HCC cells and induce apoptosis. The gene discussed is AKT1; the disease is hepatocellular carcinoma.